microtubule associated serine/threonine kinase family member 4Genealiases: []
Q-omics provides the consensus-scored MAST4 profile across patient tissues and cancer cell-line models. MAST4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAST4 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MAST4 protein abundance shows 24,296 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, KICH, and BRCA as cancer lineages where MAST4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAST4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAST4 survival associations across molecular data types. MAST4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAST4 RNA expression–survival associations across cancer types. High MAST4 expression shows unfavorable associations in LGG, but favorable associations in KIRC, HNSC, UCEC, BRCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAST4 RNA expression.
This table summarizes MAST4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MAST4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAST4 shows lower tumor expression in KICH, UCEC, THCA, BRCA and LUAD and higher tumor expression in KIRC. The KICH box plot shows higher MAST4 RNA expression in normal versus tumor tissue (log2 FC = −1.769, t-test p < 0.001).
This table shows molecular features associated with MAST4 in patient tissues and cancer cell lines. In patient samples, MAST4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MAST4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
